2022 International Congress » Parkinson’s Disease: Pharmacology and Therapy

A low-cost system using a big-data deep-learning framework for assessing physical tele-rehabilitation: a proof-of-concept

A. Olivares-Gil, JM. Ramírez-Sanz, JL. Garrido-Labrador, á. García-Bustillo, á. Arnaiz-González, JF. Díez-Pastor, J. González-Santos, JJ. González-Bernal, M. Allende-Río, F. Valiñas-Sieiro, JM. Trejo-Gabriel-Galan, E. Cubo (Burgos, Spain)

A Novel Parkinson Shoe: A potential treatment of Unresponsive Freezing of Gait in Parkinson’s Disease Patients

W. Phuenpathom, P. Panyakaew, R. Bhidayasiri (Bangkok, Thailand)

A Study of Battery Replacement Characteristics of Patients with Parkinson’s Disease and Factors Influencing Battery Drain

P. Sharma, P. Pal, D. Srinivas, N. Kamble, R. Yadav, V. Holla (Bangalore, India)

A systematic review to compare the effect of bilateral deep brain stimulation (STN versus GPI) on gait and balance in Parkinson’s disease

D. Dash, D. Vibha, T. Mestre (Ottawa, Canada)

Acute polyneuropathy in patients with Parkinson’s disease treated with LCIG

P. Havránková, R. Jech, M. Baláž, V. čapek, K. Gmitterová, M. Grófik, V. Haň, M. Kaiserová, P. Kaňovský, J. Klempíř, E. Kurča, M. Minár, J. Necpál, I. Rektorová, J. Roth, E. Růžička, M. škorvánek, P. Valkovič (Praha 2, Czech Republic)

Addressing pathological alpha-synuclein aggregation using a small molecule strategy

E. Tsika, N. Ait-Bouziad, N. Dreyfus, C. Vallet, L. Maliqi, L. Aeschbach, S. Pautet, S. Menant, I. Borovko, L. Rey-Bellet, A. Ouared, R. Migliorini, K. Piorkowska, V. Darmency, H. Kroth, S. Poli, A. Pfeifer, M. Kosco-Vilbois (Lausanne, Switzerland)

ADS024 attenuates striatal dopamine loss and restores movement in animal models of Parkinson’s disease

L. Chesnel, S. Acton (Concord, USA)

Adverse drug reactions to apomorphine: a worldwide pharmacovigilancedatabase analysis

M. Auffret, C. Le Corre, LM. Scailteux, M. Vérin, E. Polard (Rennes, France)

Alprazolam reduces freezing of gait and improves freezing-related gait measures

A. Al Jaja, T. Sue, K. Seergobin, J. Grahn, P. Macdonald (London, Canada)

Amantadine Delayed Release/Extended Release Capsules Reduce the Proportion of the Day Spent in “BAD” Time (ON with Troublesome Dyskinesia or OFF): Analysis of Phase 3 Trial Data

R. Hauser, R. Pahwa, A. Formella (Tampa, USA)

Amelioration of Levodopa-induced Dyskinesias using Genetic Silencing of Striatal CaV1.3 in Parkinsonian Rats: Impact of Sex and Advancing Age

M. Caulfield, F. Manfredsson, J. Stancati, C. Sortwell, S. Boezwinkle, M. Vanderwerp, T. Collier, K. Collier (Grand Rapids, USA)

Antidyskinetic Effects of CaV1.3 Calcium Channel Gene Silencing in Aged Male and Female Parkinsonian Macaques

K. Steece-Collier, F. Manfredsson, S. Muller, M. Caulfield, M. Vander Werp, J. Stancati, Y. Chu, I. Sandoval, T. Collier, J. Kordower (Grand Rapids, USA)

APEG-PCL Nanoparticles Containing Rifampicin Target Dopaminergic Neurons to reduce α-synuclein aggregation

D. Lin, K. Huang (Shenzhen, China)

Apomorphine Hydrochloride Injection Treatment Initiations in the Presence and Absence of an Antiemetic in People with Parkinson Disease

C. Happel, M. Grall, B. Lujan, A. Formella (Rockville, USA)

Apomorphine sublingual film patient-reported motor status response at home throughout the day

J. Obeso, K. Chaudhuri, R. Hauser, G. Jones, G. Castilla-Fernández, D. Magalhães (Madrid, Spain)

Assessment of non-motor symptoms of Parkinson’s disease in the long-term follow-up after the cell therapy

V. Chyzhyk, A. Boika, V. Ponomarev (Minsk, Belarus)

Association between dihydropyridines and dementia conversion in Parkinson’s disease

JH. Jung, SH. Jeong, SJ. Chung, HS. Yoo, K. Baik, BS. Ye, SJ. Kim, YH. Sohn, PH. Lee (Busan, Republic of Korea)

At-home prolonged adaptive deep brain stimulation improves symptoms and reduces side effects in Parkinson’s disease

C. Oehrn, S. Cernera, L. Hammer, M. Shcherbakova, A. Hahn, R. Gilron, C. Smyth, R. Wilt, S. Little, P. Starr (SAN FRANCISCO, USA)

Beta-agonists and risk of Parkinson’s disease: Meta-analysis of real-world evidence studies

A. Singh, S. Hussain, B. Antony (Hobart, Australia)

BIOMARKERS OF PARKINSONISM AND POSSIBILITIES OF PREDICTION OF THE COURSE OF PARKINSON’S DISEASE

D. Akramova, K. Daminova (Tashkent, Uzbekistan)

Botulinum Toxin Therapy for Medication and DBS Refractory Foot Dystonia of Parkinsonism

E. Zinoviev, M. Ganapathy, M. Siddiqui (Winston-Salem, USA)

Bullous skin lesions following introduction of safinamide in a woman with Parkinson’s disease

L. Lachance, P. Huot (Montreal, Canada)

Can abdominal internal oblique muscle be a possible target for ultrasound-guided Botulinum toxin injection in patients with Parkinson’s Disease affected by axials problems? An ultrasound study of our case series.

F. Marenco, P. Arcuri, M. Meloni, M. Ramella, A. Castagna (Milan, Italy)

Can we add whey protein supplementation in patients with Parkinson’s disease without interfering with levodopa response?

G. Pinelli, C. Siri, A. Ranghetti, V. Cereda, R. Maestri, M. Canesi (Gravedona, Italy)

Clinical Outcomes and Disease Burden of Advanced Parkinson’s Disease Patients Treated with Oral Medication Vs. Device-Aided Therapies: Preliminary Results from the University of Florida Registry Analysis

W. Hu, O. Ladhani, P. Kukreja, A. Ramirez-Zamora (Gainesville, USA)

Clove mediated Rescue in Parkinson’s Disease involves modulation of p53 and Sestrin2 in SHSY5Y cell line model

N. Rai, S. Dey (Udaipur, India)

Collective expert perspectives on the use of safinamide as adjunctive therapy for Parkinson’s disease in Japan: Online-based Delphi approach

A. Takeda, Y. Tsuboi, M. Nomoto, H. Mochizuki, N. Hattori (Miyagi, Japan)

Comparing duodenal levodopa infusion based on length of treatment in advanced Parkinson’s.

J. Alonso Maroto, E. Casas Peña, I. Muro García, M. Domínguez Gallego, E. Valiente Gordillo, L. López Manzanares, JA. Vivancos Mora (Madrid, Spain)

Comparison of efficacy and safety of adjunct treatments to levodopa in patients with Parkinson’s disease and wearing-off: A network meta-analysis of randomized, double-blind trials

Y. Kogo, W. Sako, M. Koebisu, H. Yamakage, T. Ishida, N. Hattori (Tokyo, Japan)

Continuous circadian intracerebroventricular administration of anaerobically preserved dopamine greatly reduces severe L-dopa-related complications in Parkinson’s disease

C. Moreau, P. Odou, A. Demailly, G. Touzet, N. Reyns, N. Carta, C. Barthelemy, D. Lannoy, B. Palas, B. Gouges, JC. Devedjian, L. Defebvre, M. Fisichella, D. Devos (Lille, France)

Continuous Dopaminergic Stimulation (CDS), different infusion rates

L. Quirós Illán, L. Ruiz-Escribano Menchen, JP. Cabello, F. Villanueva, I. Martin, A. Garcia Maruenda, P. Nieto Palomares, RE. Ibañez, J. Vaamonde Gamo (Ciudad Real, Spain)

Continuous subcutaneous apomorphine infusion for the management of Parkinson’s disease at the end-of-life

M. Bereau, M. Giffard, AL. Clairet, M. Verin, M. Auffret (Besançon, France)

Development of C-terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson’s Disease and Other Synucleinopathies

R. Barbour, A. Elmaarouf, L. Louie, S. Tam, C. Tourino, B. Campbell, G. Kinney, W. Zago (South San Francisco, USA)

DIFFERENT PATTERNS OF ACUTE SACCADIC RESPONSES TO LEVODOPA CHALLENGE TEST IN DE NOVO PARKINSON’S DISEASE: POSSIBILE PROGNOSTIC IMPLICATIONS

C. Terravecchia, G. Mostile, CG. Chisari, A. Luca, R. Terranova, G. Donzuso, CE. Cicero, G. Sciacca, A. Nicoletti, M. Zappia (Catania, Italy)

Directional DBS – Early experiences with “Current steering” in India

VM. Mathur, PD. Doshi, AA. Aundhkar, MB. Baldia, PW. Wadia (Mumbai, India)

Dopamine agonist utilization prior to the initiation of device aided therapy: data from 150 patients with advanced Parkinson’s disease treated with Levodopa Carbidopa Intestinal Gel

J. Szasz, V. Constantin, K. Orban-Kis, L. Bancu, S. Bataga, R. Neagoe, J. Szederjesi, B. Grigorescu, M. Ciorba, I. Mihaly, K. Kelemen, S. Szatmari (Targu Mures, Romania)

Effect of CDNF in a novel combination stressor model of Parkinson’s disease

A. Singh, A. Panhelainen, M. Voutilainen (Helsinki, Finland)

Effect of levodopa-carbidopa intestinal gel on lower urinary tract symptoms in Parkinson’s disease: an Urodynamic study

D. Rinaldi, O. Voglino, A. Tubaro, FE. Pontieri (rome, Italy)

Effects of a novel neurotrophic compound in an animal model of Parkinson’s disease

T. Viljakainen, M. Voutilainen (Helsinki, Finland)

EFFECTS OF DOPAMINERGIC MEDICATION ON REACTIVE AND PROACTIVE INHIBITORY CONTROL

G. Mirabella, C. Mancini, O. Olivola, A. Rizzardi, V. Di Caprio, E. Ferrari, N. Modugno, A. Pilotto, A. Padovani (Brescia, Italy)

Effects of Once-Daily Opicapone 50 mg on COMT activity: A Pooled Post-hoc Analysis of Two Phase 1 Studies

G. Loewen, A. Vijan, K. Olson, T. O'Reilly, G. Liang, O. Klepitskaya (San Dieg, USA)

EFFECTS OF OPICAPONE IN PARKINSON DISEASE AS ASSESSED BY KINEMATIC TECHNIQUES

D. Colella, A. de Biase, A. Cannavacciuolo, L. Angelini, A. Guerra, G. Paparella, A. Berardelli, G. Fabbrini, M. Bologna (Rome, Italy)

Experience with apomorphine infusion cartridge in France – evaluation of patient and healthcare team benefits

M. Vérin, M. Demais (Rennes, France)

Factors related to the antidepressant effect of safinamide in Parkinson’s disease. A post-hoc analysis of SADNESS-PD study

E. Peña, C. Borrué, M. Mata, JC. Martínez-Castrillo, A. Alonso-Canovas, JL. Chico, L. López-Manzanares, M. Llanero, J. Herreros-Rodríguez, A. Esquivel, T. Maycas-Cepeda, C. Ruíz-Huete (Madrid, Spain)

GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase show evidence of pharmacological efficacy in conduritol β-epoxide (CBE) models of Parkinson’s disease

B. Guzman, N. Perez, A. Garcia-Collazo, E. Cubero, X. Barril, M. Bellotto, A. Henriques, L. Rouviere, R. Maj (Lugano, Switzerland)

Impact of dopamine replacement therapies on MDS-UPDRS II

F. Nassan, J. Shirvan, M. Yang, T. Dam, J. Wang, N. Maserejian, W. Flanders (Brookline, USA)

Impact of GBA Mutations in the Outcomes of Deep Brain Stimulation in Parkinson’s

M. Roque, R. Barbosa, P. Pita Lobo, A. Valadas, B. Cattoni, H. Carvalho, M. Rosa, J. Ferreira, M. Coelho, L. Guedes (Lisbon, Portugal)

In Silico Study Reveals Cocaine Exposure Modulates Dopamine Neuron Firing Patterns by Inhibiting Small Conductance Calcium Activated Potassium Current

CHI. Mahapatra (Mumbai, India)

IncobotulinumtoxinA for treating chronic sialorrhea due to Parkinson’s disease and other neurological conditions

W. Jost, F. Pagan (Wolfach, Germany)

Initial experience with levodopa-entacapone-carbidopa intestinal gel infusion (LECIG) for the management of advanced Parkinson’s disease in Slovenia

E. Pipan, N. Zupančič Križnar, L. Ocepek, R. Rajnar, M. Kramberger, M. Menih, Z. Pirtošek, M. Trošt (Ljubljana, Slovenia)

Lateral shifting from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in the treatment of advanced idiopathic Parkinson’s disease (PD): Case series

M. Abu Al-Melh, M. Farghal, N. Abdelall (Ahmadi governorate, Kuwait)

Levodopa Carbidopa Intestinal Gel in Patients with Deep Brain Stimulation in Parkinson’s disease- First case series from Middle-East Region

S. Mittal, A. Aldakheel, W. Mohammed, T. Alkhairallah, B. Klassen, M. Thomas, T. Maiti, S. Wasti (Abu Dhabi, United Arab Emirates)

Levodopa Pharmacokinetics in Different Levodopa Treatment Regimens plus Opicapone in Parkinson’s Disease Patients with Motor Fluctuations

J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, J-F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

Levodopa-carbidopa intestinal gel (LCIG) as an add-on therapy to deep brain stimulation (DBS) for managing progressive symptoms of advanced idiopathic Parkinson’s disease during the COVID-19 pandemic: Case Report

M. Abu Al-Melh, M. Farghal, N. Abdelall (Ahmadi governorate, Kuwait)

Levodopa-carbidopa intestinal gel infusion and long-term tolerability in Parkinson’s: multicentre, international 13-year follow-up data

V. Leta, L. Batzu, L. Williams, S. Waller, F. Garri, K. Rukavina, M. Parry, S. Jones, J. Griffith, N. Jeyakumar, M. Scharfenort, P. Odin, V. Metta, G. Chung-Faye, P. Dubois, T. Marshall, A. Zecchinelli, F. Del Sorbo, V. Viljaharju, E. Pekkonen, A. Antonini, V. Fung, K. Ray Chaudhuri (London, United Kingdom)

Levodopa–entacapone–carbidopa intestinal gel infusion for advanced Parkinson’s disease patients – data from a Romanian center

A. Dulamea, T. Barbulescu, C. Banica (Bucharest, Romania)

Long-term follow-up of subthalamic nucleus deep brain stimulation for Parkinson’s disease: survival and disability milestones

R. Barbosa, L. Correia-Guedes, M. Cattoni, P. Pita-Lobo, A. Castro-Caldas, M. Fabbri, P. Bastos, H. Carvalho, L. Albuquerque, S. Reimão, A. Gonçalves Ferreira, J. Ferreirajos, M. Rosa, M. Coelho (Lisbon, Portugal)

Long-term Safety of Medical Cannabis in Parkinson’s disease: a retrospective case-control study

T. Goldberg, Y. Redlich, T. Fay-Karmon, S. Hassin-Baer, S. Anis (Tel Aviv, Israel)

Longitudinal Exercise is Associated with Reduced Hospitalization Risk in Parkinson’s Disease

G. Kannarkat, M. Rafferty, S. Luo, H. Liu, K. Mills (Baltimore, USA)

Magnetic Resonance Image-guided high-intensity focused ultrasound (MRIgFUS) subthalamotomy in Spanish Parkinson’s disease (PD) patients.

M. Campins-Romeu, R. Baviera-Muñoz, C. Morata-Martinez, I. Sastre-Bataller, R. Conde-Sardon, A. Gutierrez-Martin, I. Martinez-Torres (Valencia, Spain)

May apomorphine be helpful for the axial symptoms of Parkinson’s Disease?

A. Alonso-Canovas, P. Perez Torre, G. Sanchez Diez, A. Patiño Paton, N. Gonzalez, I. Parees Moreno, JC. Martinez Castrillo (Madrid, Spain)

Medication safety in Parkinson’s disease patients: evaluation of recommendations for decision support in the national drug-disease interaction database

JJ. de Jong, CCM. Stuijt, MME. Diesveld, T. van Laar, SD. Borgsteede (Groningen, Netherlands)

Multidimensional phenotyping of human stem cell-derived midbrain dopaminergic neurons from a SNCA triplication carrier for drug screening applications

J. Wilbertz, V. Gorgogietas, L. Cousin, A. Vuidel, I. Boussaad, R. Krüger, P. Sommer (Strasbourg, France)

Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson’s disease: TALISMAN study rationale and protocol

J. Janssen Daalen, M. Meinders, B. Stunnenberg, H. Groenewoud, P. Ainslie, D. Thijssen, B. Bloem (Nijmegen, Netherlands)

Natural progression of patients with Parkinson disease on less pulsatile levodopa therapy

M. Lin, R. Laureno, A. Lenka (Washington, USA)

Neurophysiological and Clinical Effects of Low-intensity Transcranial Ultrasound of the Motor Cortex in Parkinson’s Disease

T. Grippe, Y. Shamli Oghli, G. Darmani, T. Arora, C. Sarica, C. Rinchon, J. Nankoo, C. Gunraj, R. Chen (Toronto, Canada)

New-onset gait problems after bilateral STN-DBS for Parkinson’s disease: A systematic review

J. Janssen Daalen, A. Selvaraj, D. Georgiev, B. Bloem, R. Bartels, R. Esselink, S. Vinke (Nijmegen, Netherlands)

Noninvasive focal delivery of Adeno Associated Vectors (AAV) with magnetic resonance-guided focused ultrasound in non-human primates

J. Blesa, JA. Pineda-Pardo, K. Inoue, T. Balzano, N. Lopez Gonzalez-Del-Rey, A. Reinares-Sebastian, N. Esteban-Garcia, I. Trigo-Damas, M. Takada, JA. Obeso (MOSTOLES, Spain)

Nutritional Status in Advanced Parkinson’s Disease: Preliminary Results.

N. Ayo (Barakaldo, Spain)

OPICAPONE ADD-ON THERAPY IN LEVODOPA-CARBIDOPA INTESTINAL GEL INFUSION: which patient might benefit the most?

F. Colucci, V. Rispoli, V. Tugnoli, M. Pugliatti, G. Tecilla, M. Sensi (Ferrara, Italy)

Opicapone use in patients with Parkinson’s disease with motor fluctuations: experience from a tertiary center

E. Ojeda-Lepe, L. Muñoz-Delgado, S. Jesús, AD. Adarmes-Gómez, D. Macías-García, MV. Jiménez Jaraba, B. Benítez Zamora, F. Carrillo, P. Mir (Seville, Spain)

Parkinson’s patient insights, knowledge and experience of treatment – results from a multicountry survey

F. de Renzis, L. Graham, M. Meinders (Orpington, United Kingdom)

Phantom Pregnancy – A Novel Impulse Control Behaviour in Parkinson’s Disease: A Case Report

H. Martin, L. Teare (Coventry, United Kingdom)

Pharmacological activation of Rev-erbα Provides Neuroprotection against Parkinson’s Disease

L. Kou (Wuhan, China)

Phosphorylated α-synuclein at serine residue 129 decreased in Parkinson’s disease patients taking 250mg of daily niacin for six months

C. Wakade, M. Seamon, S. Purohit, J. Morgan, R. Chong (Augusta, USA)

Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)

C. Vermeiren, A. Ates, F. Bouzom, A. Delaunois, M. Gillard, B. Kenda, A. Ousset, L. Provins, D. Skolc, A. Valade, M. Vanmeulder, M. Wood, Y. Lamberty (Braine-l'Alleud, Belgium)

Protective approach targeting NF-kB/ Nrf2 signaling and neuroinflammation using Apigenin in LPS induced Parkinsonism in experimental rats

S. Singh (Moga, India)

Relative bioavailability of levodopa administered as a subcutaneous infusion with ND0612 versus oral immediate-release levodopa/carbidopa tablets

L. Adar, N. Vostokova (Rehovot, Israel)

Reported Clinical and Quality-of-Life Outcomes With 24-Hour Levodopa-Carbidopa Intestinal Gel Administration Compared With 16-Hour Administration

N. Kovács, M. Simu, O. Sanchez Soliño, J. Parra, J. Alcazar, S. Snedecor, V. Fung (Pécs, Hungary)

Response of freezing, posture and voice to increasing levodopa doses in Parkinson’s disease

G. Imbalzano, D. Rinaldi, G. Calandra Buonaura, M. Contin, F. Amato, G. Giannini, L. Sambati, C. Ledda, A. Romagnolo, G. Olmo, P. Cortelli, M. Zibetti, C. Artusi, L. Lopiano (Torino, Italy)

Safety of opicapone after 5 years of post-marketing experience worldwide

L. Guedes, J. Graça, M. Sampaio, M. Vieira, F. Rocha, H. Gama (Coronado, Portugal)

Safinamide adherence: the experience of the movement disorder unit of Trieste.

M. Catalan, M. Liccari, V. Tommasini, L. Antonutti, P. Manganotti (Trieste, Italy)

SAFINAMIDE: REAL LIFE STUDY. EFFICACY IN SWITCH FROM RASAGILINA AND LOW-DOSE TREATMENT.

MI. Morales-Casado, N. López-Ariztegui, DD. García-Meléndez, A. Diezma-Martín (Toledo, Spain)

Satisfaction level: quality of life, motor and non-motor symptoms outcomes of Mexican PD patients after deep brain stimulation.

P. Bazán-Rodríguez, E. Reséndiz-Henríquez, E. Ichikawa-Escamilla, AJ. Hernández-Medrano, GI. Cerda-Hernández, MA. Ruiz-Mafud, L. Bazán-Rodríguez, C. Martínez-Cortés, RA. Abundes-Corona, A. Cervantes-Arriaga, M. Rodríguez-Violante (Mexico City, Mexico)

Silencing dopamine neurons during sleep slows disease progression in parkinsonian mice

C. Meng, G. Cui (Research Triangle Park, USA)

Striatal Blood brain barrier opening in Parkinson´s disease

C. Gasca-Salas, J. Pineda-Pardo, B. Fernández-Rodríguez, I. Obeso, F. Hernández-Fernández, C. Trompeta, R. Martínez-Fernández, M. Matarazzo, D. Mata-Marín, P. Guida, G. Foffani, G. Toltsis, I. Rachmilevitch, J. Blesa, R. Rodríguez-Rojas, M. Del-Alamo, J. Obeso (Móstoles, Spain)

Systematic Review and Network Meta-Analysis of COMT and MAO-B Inhibitors in Parkinson’s Patients with Motor Fluctuations

G. Castilla-Fernández, M. Fonseca, J. Ferreira, J-F. Rocha (Coronado, Portugal)

The anti-alpha-synuclein antibody Lu AF82422 binds to pathological alpha-synuclein species from human brains and inhibits seeded alpha-synuclein aggregation

P. Kallunki, K. Willén, F. Sotty, L. Buur, K. Bjerregaard-Andersen, M. Lubas, D. Damlund, M. Harndahl, K. Fog (Valby, Denmark)

The benefit of exclusive nocturnal administration of a levodopa-carbidopa intestinal infusion for severe refractory sleep behavior disorder in Parkinson’s disease

M. Rivera Sánchez, A. Sánchez Rodríguez, M. Sierra, I. González-Aramburu, MV. Sánchez Peláez, M. Martínez, J. Infante (Santander, Spain)

The effect of co-administration of opicapone on the pharmacokinetics of levodopa

D. Kamiyama, N. Nishikawa, G. Oyama, T. Hatano, N. Hattori (Tokyo, Japan)

The effect of rasagiline on nocturnal hypokinesia: the analysis of the Nocturnal Hypokinesia Questionnaire (NHQ)

J. Sringean, R. Bhidayasiri (Bangkok, Thailand)

The effects of on-demand auditory cueing on home-based freezing of gait in people with Parkinson’s disease

D. Zoetewei, T. Herman, L. Palmerini, A. Ferrari, J. Hausdorff, A. Nieuwboer, P. Ginis (Leuven, Belgium)

Therapeutic potential of luteolin in manganese induced Parkinson’s disease: Targeting neuroinflammation and oxidative stress.

S. Chib (Moga, India)

Therapy resistant tremor in Parkinson’s disease. Satisfying an unmet need.

SW. Pedersen, L. Johannsen (Frederiksberg, Denmark)

To Prescribe or Not to Prescribe: Assessing the impact of Parkinson’s nurse prescribers

A. Hand, K. Mcewan, A. Clarke, A. Bate, S. Dalkin, R. Bradford, C. Allen, K. Mcdonald, S. Mccarthy, K. Brittain (Newcastle upon Tyne, United Kingdom)

Transcutaneous auricular vagal nerve stimulation has frequency depended propensity to improve gait in Parkinson’s disease – a pilot study

V. van Midden, Z. Pirtošek, G. Brecl Jakob, M. Kojović (Ljubljana, Slovenia)

Understanding the continuing educational needs of US clinicians managing OFF episodes in Parkinson’s disease

W. Cerenzia, S. Wiley, B. Coleman, S. Stacy, E. Jen, K. Farahmand (Birmingham, USA)

Use of alternative healing for Parkinson’s disease in Kenya

N. Fothergill-Misbah, R. Walker (Southampton, United Kingdom)

Use of apomorphine infusion pump in the elderly population : a 5 years follw up study on efficacy, safety and tolerability in a cohort bases study

C. Borrue- Fernandez, M. Mata, C. Jimeno, M. Almarcha (San Sebastian Reyes, Spain)

USE OF NIGHT TIME CONTINUOUS SUBCUTANEOUS INFUSION OF APOMORPHINE (NCSAI) IN ADVANCED PARKINSON’S DISEASE: A SERIES OF 37 CASES.

AK. Vargas Mendoza, B. López López, M. Díaz Castela, J. Molina Gil, P. Zunzunegui Arroyo, A. Criado Antón, ME. Suárez Sanmartín, C. García Fernández (Oviedo, Spain)

Variability of Plasma Levodopa Conveniently Reduced by More Frequent Administration of Smaller Doses of Carbidopa/Levodopa Using a Novel Functionally Scored Formulation

A. Al-Sabbagh, S. Testino, M. Koga, T. Chase, K. Smith (Alpharetta, USA)